Of the 23 analysts covering Sarepta Therapeutics (SRPT), 22 have given it “buy” or higher ratings, and one has given it a “hold.”
Analysts’ mean rating for Sarepta stock is 1.65, and their target price is $195.43, implying a potential 89.5% upside for the stock based on its December 19 closing price of $103.11.
In comparison, peers Pfizer (PFE), Regeneron (REGN), and Vertex Pharmaceuticals (VRTX) have received mean ratings of 2.72, 2.58, and 1.84, respectively, and target prices of $44.15, $426.05, and $201.82, respectively, from analysts.
Sarepta’s current ratio, which shows how effectively it can meet its short-term obligations, is 8.80x. In comparison, Pfizer’s, Regeneron’s, and Vertex’s current ratios are 1.40x, 4.0x, and 3.70x, respectively.
After a stellar rise from $55.14 on February 9 to a high of $161.51 on September 28, Sarepta stock corrected to $111.99 on November 14. Since then, after initial buying interest took it to $130.97 on December 3, Sarepta stock has again corrected to its current $103 level amid broader market fluctuations.
In the third quarter, Sarepta’s average number of outstanding shares increased YoY to ~66.21 million from ~61.53 million. Its outstanding shares totaled ~42.29 million in 2015 and ~48.7 million in 2016. This number is expected to increase to ~71.35 million in 2020, indicating shareholder dilution.
Sarepta’s long-term debt-to-equity ratio is 0.65x, whereas its peers Pfizer, Regeneron, and Vertex have debt-to-equity ratios of 0.47x, 0.09x, and 0.20x, respectively.